Co-Diagnostics, Inc. (CODX) income statement

CODXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30

$0.27−0.01 (-2.92%)

Close on Nov 12, 2026Market cap $1.69MP/E –Yield –

Co-Diagnostics, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31
Revenue	0.62	3.92	6.81	34	98	75	0.21	0.04	0.01	–
Cost of Revenue	0.22	1.00	4.18	5.48	12	17	0.11	0.01	0.00	–
Gross Profit	0.40	2.92	2.63	29	86	58	0.10	0.03	0.01	–
Research & Development	19	21	23	17	15	3.19	1.37	1.36	1.00	0.73
Selling, General & Admin	11	21	21	22	25	13	4.56	4.74	3.52	0.92
Selling & Marketing	2.38	4.48	6.86	7.34	13	4.67	1.06	1.17	0.43	0.12
General & Administrative	9.06	16	14	14	12	8.28	3.50	3.57	3.10	0.80
Operating Expenses	51	43	45	56	40	16	6.00	6.15	4.57	1.69
Operating Income	-50	-40	-43	-27	46	42	-5.89	-6.12	-4.56	-1.69
Interest Expense	–	–	–	–	–	–	0.11	0.07	0.31	0.24
Interest & Investment Income	0.29	1.09	1.16	0.70	0.05	0.10	0.04	0.02	0.00	–
Other Non-Operating Income	1.65	2.50	4.60	8.13	-0.43	0.88	-0.30	-0.15	-2.40	–
Asset Impairment Charges	19	–	0	15	–	–	–	–	–	–
Gain (Loss) on Investments	-0.05	-0.19	0.10	-0.33	-0.43	0.78	–	–	–	–
Gain (Loss) on Sale of Assets	-0.08	0.01	0.00	-0.14	-0.04	0.00	0.00	–	–	–
Pretax Income	-49	-38	-38	-19	46	43	-6.20	-6.27	-6.96	-1.93
Income Tax Expense	-1.62	0.06	-2.78	-4.61	8.98	0.09	–	–	–	–
Net Income	-47	-38	-35	-14	37	42	-6.20	-6.27	-6.96	-1.93
EPS (Basic)(per share)	-35.25	-37.22	-36.00	-13.50	38.10	47.70	-11.10	-15.00	-18.90	–
EPS (Diluted)(per share)	-35.25	-37.22	-36.00	-13.50	36.90	45.60	-11.10	-15.00	-18.90	–
Shares Outstanding (Basic, Weighted)(shares)	1.33	1.01	0.98	1.05	0.96	0.89	0.56	0.42	0.37	0.33
Shares Outstanding (Diluted, Weighted)(shares)	1.33	1.01	0.98	1.05	1.00	0.93	0.56	0.42	0.37	0.33
EBITDA	-49	-39	-41	-26	46	42	-5.83	-6.07	-4.52	-1.65

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Sep 30, 2026

Profitability, TTM

Gross margin: 20.3%
Operating margin: -5614.3%
Net margin: -5527.6%
Return on equity, FY2025: -125.9%

Financial strength

Current ratio: 0.77
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 28.5%

Valuation

P/E ratio: –
Price to sales: 1.96
Price to book: 0.18
Dividend yield: –

See a number that looks wrong?